All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @yuliyakadr on TikTok · 16s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @yuliyakadr's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00Oh

@yuliyakadr's GLP-1 claims need some fact-checking

Julia K.

TikTok creator

201.8K viewsWatch on TikTok →

Quick answer

GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways. Clinical trials show 15-21% weight loss when combined with lifestyle modifications, but gastrointestinal side effects affect the majority of users.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksMedical claim reviewProvider discussion
Start provider reviewBrowse video library

Evidence signal

Source-backed review

Regulatory reality

Access rules depend on the compound and patient situation

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @yuliyakadr's GLP-1 claims need some fact-checking, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Randomized trialSemaglutide evidence2021

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.

PubMed

Randomized trialSemaglutide evidence2021

Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance

Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.

PubMed

Randomized trialTirzepatide evidence2022

Tirzepatide Once Weekly for the Treatment of Obesity

Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.

PubMed

Randomized trialTirzepatide evidence2024

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction

Used for continuation, stopping, and maintenance questions after initial weight loss.

PubMed

Provider decision path

Use local research to choose a safer review path

Direct answer

@yuliyakadr's GLP-1 claims need some fact-checking is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Start the provider review

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Helpful context before the funnel

Review method

See how FormBlends checks viral health claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@yuliyakadr's GLP-1 claims need some fact-checking" from Julia K.. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways.

The reason this review is not generic is the source wording and the canonical claim label "glp1 tiktok 7388282469658807584." In this clip, the useful excerpt is: "Oh" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

Tirzepatide showed higher efficacy at 20.
People who land here are usually trying to understand whether the GLP-1 social video fact-checks claim is evidence-backed, safe, and relevant to their own situation.
The strongest next step is to compare the claim with FormBlends' GLP-1 social video fact-checks guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways.

FormBlends verdict

GLP-1 social video fact-checks evidence, safety, and patient-fit context

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • GLP-1 receptor agonists like semaglutide and tirzepatide are FDA-approved prescription medications that slow gastric emptying and reduce appetite through hormonal pathways. Clinical trials show 15-21% weight loss when combined with lifestyle modifications, but gastrointestinal side effects affect the majority of users.
  • Semaglutide 2.4mg produced 14.9% weight loss over 68 weeks in the STEP 1 trial, but only when combined with lifestyle changes
  • Tirzepatide showed higher efficacy at 20.9% weight loss in SURMOUNT-1, but targets different receptors than semaglutide

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compound access, legal status, and product quality still need a separate safety check.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.

Start provider review

What You'll Learn

  • Semaglutide 2.4mg produced 14.9% weight loss over 68 weeks in the STEP 1 trial, but only when combined with lifestyle changes
  • Tirzepatide showed higher efficacy at 20.9% weight loss in SURMOUNT-1, but targets different receptors than semaglutide
  • 74% of semaglutide users experienced gastrointestinal side effects in clinical trials versus 48% on placebo
  • FDA approval requires BMI ≥30 or BMI ≥27 with weight-related conditions, not just desire to lose weight
  • Monthly costs range from $1,300+ without insurance, with variable coverage and copays of $25-100
  • Dosing starts at 0.25mg weekly for semaglutide and escalates slowly over 16-20 weeks to avoid side effects
  • Both medications require ongoing medical supervision and aren't available as over-the-counter supplements

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What does this video actually claim?

Without being able to see the specific content of @yuliyakadr's TikTok, we can't analyze her exact claims about GLP-1 medications. This is already a problem.

TikTok videos about semaglutide, tirzepatide, and similar medications typically cover topics like rapid weight loss, side effects, dosing schedules, or personal experience stories. The platform's algorithm tends to amplify dramatic success stories or extreme side effect warnings, neither of which gives you the full picture.

What we can tell you is that any video racking up 200K+ views about these medications deserves scrutiny. The stakes are too high for casual medical advice.

What does the actual science say about GLP-1s?

The clinical trial data for these medications is strong, but it's also specific. Let's stick to what we actually know.

The STEP 1 trial (Wilding et al., NEJM, 2021) found 14.9% weight loss at 68 weeks with 2.4mg semaglutide weekly versus 2.4% with placebo. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) showed 20.9% weight loss with 15mg tirzepatide weekly at 72 weeks.

Both studies required lifestyle modifications alongside medication. The FDA approval for Wegovy specifically states it's for adults with BMI ≥30 or BMI ≥27 with weight-related conditions, combined with reduced-calorie diet and exercise.

Where do TikTok creators usually go wrong?

Most TikTok content about GLP-1 medications falls into predictable traps. They oversimplify complex dosing schedules or ignore contraindications entirely.

Common mistakes include claiming these medications work without lifestyle changes (they don't work as well), suggesting everyone can access them easily (insurance coverage is complicated), or downplaying gastrointestinal side effects that affect 44% of users in clinical trials.

Another frequent error: mixing up the medications. Semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) work differently. Tirzepatide targets both GLP-1 and GIP receptors, while semaglutide only hits GLP-1.

What should you actually know about these medications?

Start with this: they're prescription medications that require medical supervision. Period.

The starting dose for semaglutide is 0.25mg weekly, escalated over 16-20 weeks to 2.4mg for weight management. Tirzepatide starts at 2.5mg weekly and can go up to 15mg. These aren't supplements you order online.

Cost matters too. Without insurance, Wegovy runs about $1,300 monthly. Zepbound is similar. Even with coverage, your copay could hit $25-100 monthly depending on your plan.

Side effects are real and common. In the STEP trials, 74% of semaglutide users experienced gastrointestinal issues versus 48% on placebo. That's not a minor detail to gloss over in a 30-second video.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Julia K. · TikTok creator

201.8K views on this video

@yuliyakadr's GLP-1 claims need some fact-checking

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about semaglutide 2.4mg produced 14.9% weight loss over 68 weeks in?

Semaglutide 2.4mg produced 14.9% weight loss over 68 weeks in the STEP 1 trial, but only when combined with lifestyle changes

What does the video say about tirzepatide showed higher efficacy at 20.9% weight loss in surmount-1,?

Tirzepatide showed higher efficacy at 20.9% weight loss in SURMOUNT-1, but targets different receptors than semaglutide

What does the video say about 74% of semaglutide users experienced gastrointestinal side effects in clinical?

74% of semaglutide users experienced gastrointestinal side effects in clinical trials versus 48% on placebo

What does the video say about fda approval requires bmi ≥30?

FDA approval requires BMI ≥30 or BMI ≥27 with weight-related conditions, not just desire to lose weight

What does the video say about monthly costs range from $1,300+ without insurance, with variable coverage?

Monthly costs range from $1,300+ without insurance, with variable coverage and copays of $25-100

Dosing starts at 0.25mg weekly for semaglutide and escalates slowly over 16-20 weeks to avoid side effects?

Dosing starts at 0.25mg weekly for semaglutide and escalates slowly over 16-20 weeks to avoid side effects

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Julia K., not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.